News
An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...
Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...
The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...
With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...
AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...
Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.
2d
Barchart on MSNAre Wall Street Analysts Bullish on Gilead Sciences Stock?
Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...
19h
Asianet Newsable on MSNPheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic
On Stocktwits, retail sentiment around Pheton is trending in the ‘extremely bullish’ territory, coupled with ‘extremely high’ ...
Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results